• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

lois@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0001-6137-9171

Prof Sherene Loi

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

807 Scholarly works
44 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
    DOI: 10.1038/s41467-026-75660-y
  • 2026

    Journal article

    Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge
    DOI: 10.1038/s41467-026-72956-x
  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Innovating in Breast Cancer Immunology Treatment and Prevention
  • 2022

    Journal article

    Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
    DOI: 10.1038/s43018-022-00413-x
  • 2021

    Journal article

    Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
    DOI: 10.1093/jnci/djab111
  • 2018

    Research Grant

    Capture: Circulating Tumour Dna Assessment of Pik3ca to Guide Treatment Response
  • 2018

    Research grants (other domestic)

    2018 NBCF Endowed Chair Program
Sherene Loi

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial
    DOI: 10.1016/S1470-2045(26)00247-0
  • 2026

    Journal article

    Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group
    DOI: 10.1016/S1470-2045(26)00255-X
  • 2026

    Journal article

    Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
    DOI: 10.1016/j.annonc.2026.05.707
  • 2026

    Journal article

    Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study
    DOI: 10.1016/S1470-2045(26)00339-6
  • 2026

    Journal article

    Germline BRCA1 pathogenic variants and T cell dysfunction
    DOI: 10.1016/j.iotech.2026.101601
  • 2026

    Journal article

    Timing of breast cancer diagnosis postpartum and survival in women with germline pathogenic variants
    DOI: 10.1016/j.esmoop.2026.108346
  • 2026

    Journal article

    Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation
    DOI: 10.1016/j.esmoop.2026.108316
  • 2026

    Journal article

    The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial
    DOI: 10.1093/jnci/djag095

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224